EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Significance and Primary–Metastatic Differences in VASH1 Expression, CD34-Defined Microvessel Density, and VEGF Expression in Colorectal Cancer

Oktay Halit Aktepe iD, Rezan Berkay Izgor iD, Ozlem Aydin Isak, Olcay Kurtulan, Tugce Ulasli, Suayib Yalcin

International Journal of Molecular Sciences · 16.07.2026 · 27 (14) · 6319

DOI: 10.3390/ijms27146319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.07.2026. Verfasst von Oktay Halit Aktepe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dokuz Eylul University, Izmir 35330, Türkiye. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Vascular Endothelial Growth Factor A, Antigens, CD34, Microvascular Density. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hacettepe University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the prognostic significance of vasohibin-1 (VASH1) expression, cluster of differentiation 34 (CD34)-defined microvessel density (MVD), and vascular endothelial growth factor (VEGF) expression, as well as the differences in these parameters between primary and metastatic colorectal cancer (CRC) lesions. Tissue microarrays were used to quantify VASH1 and VEGF expression and CD34-defined MVD. Receiver operating characteristic (ROC) analysis identified optimal cut-off values for overall survival (OS). Correlations among markers were analyzed with Spearman’s test, paired tissue comparisons by the Wilcoxon signed-rank test, and survival outcomes by Kaplan–Meier and Cox regression analyses. The study included 144 CRC patients (median age: 60 years; 59% male). ROC analysis determined optimal thresholds of 6 for VASH1 (area under the curve [AUC]: 0.79, 95% confidence interval [CI]: 0.72–0.87), 37 for CD34-defined MVD (AUC: 0.76, 95% CI: 0.68–0.84), and 6 for VEGF (AUC: 0.67, 95% CI: 0.58–0.76). Patients with high VASH1 expression, high CD34-defined MVD, and high VEGF expression had significantly shorter OS compared with their corresponding low-marker groups (VASH1, p < 0.001; CD34-defined MVD, p < 0.001; VEGF, p = 0.007). Among the 45 patients with paired primary and metastatic samples, metastatic lesions showed significantly lower VASH1 and VEGF expression and lower CD34-defined MVD than matched primary tumors, with median values decreasing from 6.0 to 4.0 for VASH1 (p = 0.002), from 4 to 3 for VEGF (p < 0.001), and from 32 to 27 for CD34-defined MVD (p < 0.001). In multivariate analysis, high VASH1 expression (hazard ratio [HR]: 2.05, 95% CI: 1.01–4.20, p = 0.048) and high CD34-defined MVD (HR: 2.12, 95% CI: 1.15–3.89, p = 0.015) remained independent predictors of poor OS. High VASH1 expression and high CD34-defined MVD were independent adverse prognostic factors for OS in CRC. Lower angiogenesis-related marker levels in metastatic lesions suggest heterogeneity in tumor angiogenesis. External validation is required before clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsVascular Endothelial Growth Factor AAntigens, CD34Microvascular DensityCell Cycle ProteinsHumansMaleFemaleMiddle AgedPrognosisAgedBiomarkers, TumorNeoplasm MetastasisAdultROC CurveNeovascularization, PathologicMicrovesselsKaplan-Meier Estimate

Stichwörter der Autor:innen

angiogenesiscolorectal cancermicrovessel densityprognostic biomarkersvasohibin-1

Substanzen

Vascular Endothelial Growth Factor AAntigens, CD34VASH1 protein, humanCell Cycle ProteinsBiomarkers, TumorVEGFA protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Dokuz Eylul University, Izmir 35330, Türkiye.
  • Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir 35330, Türkiye.
  • Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Türkiye.
  • Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye.
  • Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Türkiye.

ORCID-Profile: Oktay Halit Aktepe, Rezan Berkay Izgor

Förderung

  • Hacettepe University

Zitieren

APA

Aktepe, O. H., Izgor, R. B., Aydin Isak, O., Kurtulan, O., Ulasli, T., & Yalcin, S. (2026). Prognostic Significance and Primary–Metastatic Differences in VASH1 Expression, CD34-Defined Microvessel Density, and VEGF Expression in Colorectal Cancer. International Journal of Molecular Sciences, 27(14), 6319. https://doi.org/10.3390/ijms27146319

Vancouver

Aktepe OH, Izgor RB, Aydin Isak O, Kurtulan O, Ulasli T, Yalcin S. Prognostic Significance and Primary–Metastatic Differences in VASH1 Expression, CD34-Defined Microvessel Density, and VEGF Expression in Colorectal Cancer. International Journal of Molecular Sciences. 2026;27(14):6319. doi:10.3390/ijms27146319

BibTeX
@article{Aktepe2026,
  author = {Aktepe, Oktay Halit and Izgor, Rezan Berkay and Aydin Isak, Ozlem and Kurtulan, Olcay and Ulasli, Tugce and Yalcin, Suayib},
  title = {Prognostic Significance and Primary–Metastatic Differences in VASH1 Expression, CD34-Defined Microvessel Density, and VEGF Expression in Colorectal Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6319},
  doi = {10.3390/ijms27146319}
}
Kostenlos starten →